Study identification

PURI

https://redirect.ema.europa.eu/resource/33587

EU PAS number

EUPAS33586

Study ID

33587

Official title and acronym

Risk of angiotensin converting enzyme inhibitor intolerance in asthma compared to the general population

DARWIN EU® study

No

Study countries

United Kingdom

Study description

This study will examine the risk of intolerance to angiotensin converting enzyme (ACE) inhibitors in asthma compared to the general population. Intolerance will be defined by switching to an angiotensin-II receptor blocker after initiation of ACE inhibitor therapy.

Study status

Ongoing
Research institutions and networks

Institutions

University of Dundee
United Kingdom
First published:
01/02/2024
InstitutionEducational Institution

Contact details

Daniel Morales

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Non-for-profit organisation (e.g. charity)
Other

More details on funding

Tenovus Scotland, Internal University of Dundee resources
Study protocol
Initial protocol
English (179.86 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable